Type	type	NN	O
2	2	CD	O
diabetes	diabetes	NN	O
mellitus	mellitus	NN	O
T2DM	T2DM	NNP	O
is	be	VBZ	O
a	a	DT	O
complex	complex	JJ	O
chronic	chronic	JJ	O
disease	disease	NN	O
characterised	characterise	VBN	O
by	by	IN	O
metabolic	metabolic	JJ	O
disorder	disorder	NN	O
and	and	CC	O
hyperglycaemia	hyperglycaemia	NN	O
due	due	JJ	O
to	to	IN	O
insulin	insulin	NN	O
resistance	resistance	NN	O
,	,	,	O
hepatic	hepatic	JJ	O
glucose	glucose	NN	O
overproduction	overproduction	NN	O
and/or	and/or	CC	O
insufficient	insufficient	JJ	O
insulin	insulin	NN	O
secretion	secretion	NN	B
.	.	.	O

Although	although	IN	O
there	there	EX	O
are	be	VBP	O
a	a	DT	O
number	number	NN	O
of	of	IN	O
pharmacotherapy	pharmacotherapy	NN	O
options	option	NNS	O
for	for	IN	O
T2DM	T2DM	NNP	O
,	,	,	O
most	most	JJS	O
of	of	IN	O
current	current	JJ	O
anti	anti	JJ	O
-	-	JJ	O
diabetes	diabetes	JJ	O
drug	drug	NN	O
have	have	VBP	O
shown	show	VBN	O
known	know	VBN	O
adverse	adverse	JJ	O
effects	effect	NNS	O
and	and	CC	O
loss	loss	NN	O
of	of	IN	O
their	-PRON-	PRP$	O
overall	overall	JJ	O
efficacy	efficacy	NN	O
in	in	IN	O
a	a	DT	O
long	long	JJ	O
-	-	HYPH	O
term	term	NN	O
glycaemic	glycaemic	JJ	O
control	control	NN	B
.	.	.	O

Thus	thus	RB	O
,	,	,	O
there	there	EX	O
is	be	VBZ	O
still	still	RB	O
a	a	DT	O
critical	critical	JJ	O
need	need	NN	O
of	of	IN	O
novel	novel	JJ	O
therapeutic	therapeutic	JJ	O
targets	target	NNS	O
or	or	CC	O
approaches	approach	NNS	O
for	for	IN	O
treatment	treatment	NN	O
T2DM	T2DM	NNP	O
by	by	IN	O
good	good	JJ	O
glycaemic	glycaemic	JJ	O
control	control	NN	O
.	.	.	O

G	g	NN	O
protein	protein	NN	O
-	-	HYPH	O
coupled	couple	VBN	O
receptor	receptor	NN	O
119	119	CD	O
GPR119	GPR119	NNP	O
is	be	VBZ	O
a	a	DT	O
member	member	NN	O
of	of	IN	O
class	class	NN	O
A	a	NN	O
rhodopsin	rhodopsin	NN	O
-	-	HYPH	O
type	type	NN	O
GPCR	GPCR	NNP	O
family	family	NN	O
,	,	,	O
with	with	IN	O
highly	highly	RB	O
expressed	express	VBN	O
in	in	IN	O
pancreatic	pancreatic	JJ	O
Î²-cells	î²-cell	NNS	O
and	and	CC	O
the	the	DT	O
K	K	NNP	O
and	and	CC	O
L	L	NNP	O
cells	cell	NNS	O
of	of	IN	O
the	the	DT	O
gastrointestinal	gastrointestinal	JJ	O
tract	tract	NN	B
.	.	.	O

Activation	activation	NN	O
of	of	IN	O
GPR119	GPR119	NNP	O
increases	increase	VBZ	O
the	the	DT	O
intracellular	intracellular	JJ	O
cyclic	cyclic	NN	O
AMP	AMP	NNP	O
cAMP	camp	NN	O
level	level	NN	O
,	,	,	O
which	which	WDT	O
in	in	IN	O
turn	turn	NN	O
directly	directly	RB	O
stimulate	stimulate	VBP	O
the	the	DT	O
glucose	glucose	NN	O
-	-	HYPH	O
dependent	dependent	JJ	O
insulin	insulin	NN	O
secretion	secretion	NN	O
and	and	CC	O
regulate	regulate	VB	O
glucagon	glucagon	NN	O
-	-	HYPH	O
like	like	JJ	O
peptide	peptide	NN	O
1	1	CD	O
GLP-1	GLP-1	NNP	O
,	,	,	O
leading	lead	VBG	O
to	to	TO	O
improve	improve	VB	O
the	the	DT	O
glucose	glucose	NN	O
tolerance	tolerance	NN	O
in	in	IN	O
T2DM	t2dm	NN	O
patients	patient	NNS	B
.	.	.	O

In	in	IN	O
addition	addition	NN	O
,	,	,	O
GPR119	GPR119	NNP	O
agonists	agonist	NNS	O
showed	show	VBD	O
Î²-cells	î²-cell	NNS	O
function	function	NN	O
preservation	preservation	NN	O
,	,	,	O
which	which	WDT	O
is	be	VBZ	O
also	also	RB	O
an	an	DT	O
important	important	JJ	O
role	role	NN	O
in	in	IN	O
current	current	JJ	O
T2DM	t2dm	NN	O
therapy	therapy	NN	B
.	.	.	O

As	as	IN	O
a	a	DT	O
result	result	NN	O
,	,	,	O
GPR119	GPR119	NNP	O
agonists	agonist	NNS	O
are	be	VBP	O
used	use	VBN	O
for	for	IN	O
discovery	discovery	NN	O
of	of	IN	O
anti	anti	JJ	O
-	-	JJ	O
T2DM	t2dm	JJ	O
agents	agent	NNS	O
by	by	IN	O
lowering	lower	VBG	O
the	the	DT	O
blood	blood	NN	O
glucose	glucose	VBP	O
level	level	NN	O
and	and	CC	O
improving	improve	VBG	O
Î²-cells	î²-cell	NNS	O
function	function	NN	O
.	.	.	O

Indeed	indeed	RB	O
,	,	,	O
numerous	numerous	JJ	O
synthetic	synthetic	JJ	O
,	,	,	O
small	small	JJ	O
molecule	molecule	NN	O
GPR119	GPR119	NNP	O
agonists	agonist	NNS	O
were	be	VBD	O
revealed	reveal	VBN	O
by	by	IN	O
academia	academia	NN	O
and	and	CC	O
industry	industry	NN	O
to	to	IN	O
date	date	NN	O
,	,	,	O
and	and	CC	O
some	some	DT	O
of	of	IN	O
which	which	WDT	O
have	have	VBP	O
advanced	advance	VBN	O
into	into	IN	O
clinical	clinical	JJ	O
trials	trial	NNS	O
such	such	JJ	O
as	as	IN	O
MBX-2982	MBX-2982	NNP	O
,	,	,	O
BMS-903452	BMS-903452	NNP	O
,	,	,	O
LEZ763	LEZ763	NNP	O
,	,	,	O
ZYG-19	zyg-19	VB	B
.	.	.	O

Despite	despite	IN	O
tremendous	tremendous	JJ	O
endeavours	endeavour	NNS	O
,	,	,	O
none	none	NN	O
of	of	IN	O
GPR119	GPR119	NNP	O
agonists	agonist	NNS	O
were	be	VBD	O
approved	approve	VBN	O
to	to	IN	O
market	market	NN	O
by	by	IN	O
FDA	FDA	NNP	O
up	up	IN	O
to	to	IN	O
now	now	RB	O
.	.	.	O

In	in	IN	O
our	-PRON-	PRP$	O
efforts	effort	NNS	O
to	to	TO	O
discover	discover	VB	O
GPR119	GPR119	NNP	O
agonists	agonist	NNS	O
,	,	,	O
we	-PRON-	PRP	O
previously	previously	RB	O
have	have	VBP	O
evaluated	evaluate	VBN	O
some	some	DT	O
series	series	NN	O
of	of	IN	O
pyrimidine	pyrimidine	JJ	O
derivatives	derivative	NNS	O
,	,	,	O
and	and	CC	O
some	some	DT	O
compounds	compound	NNS	O
displayed	display	VBD	O
quite	quite	RB	O
good	good	JJ	O
agonistic	agonistic	JJ	O
potency	potency	NN	B
,	,	,	B
.	.	.	O

Among	among	IN	O
them	-PRON-	PRP	O
,	,	,	O
pyrimidopyrimidine	pyrimidopyrimidine	JJ	O
compounds	compound	VBZ	O
1	1	CD	O
and	and	CC	O
2	2	CD	O
exhibited	exhibit	VBN	O
single	single	JJ	O
digit	digit	NN	O
EC50	EC50	NNP	O
values	value	NNS	O
2.2ânM	2.2ânm	CD	O
and	and	CC	O
8.1ânM	8.1ânm	CD	O
respectively	respectively	RB	O
;	;	:	O
however	however	RB	O
,	,	,	O
these	these	DT	O
two	two	CD	O
agonists	agonist	NNS	O
did	do	VBD	O
not	not	RB	O
show	show	VB	O
the	the	DT	O
significant	significant	JJ	O
glucose	glucose	NN	O
-	-	HYPH	O
lowering	lower	VBG	O
effect	effect	NN	O
in	in	IN	O
oral	oral	JJ	O
glucose	glucose	NN	O
tolerance	tolerance	NN	O
test	test	NN	O
oGTT	ogtt	NN	O
in	in	IN	O
mice	mouse	NNS	O
compared	compare	VBN	O
with	with	IN	O
positive	positive	JJ	O
control	control	NN	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
we	-PRON-	PRP	O
sequentially	sequentially	RB	O
attempted	attempt	VBD	O
to	to	TO	O
optimise	optimise	VB	O
the	the	DT	O
core	core	NN	O
fragment	fragment	NN	O
with	with	IN	O
the	the	DT	O
aim	aim	NN	O
to	to	TO	O
enhance	enhance	VB	O
the	the	DT	O
biological	biological	JJ	O
activity	activity	NN	O
both	both	CC	O
inÂ	inâ	JJ	O
vitro	vitro	FW	O
and	and	CC	O
inÂ	inÂ	NNP	O
vivo	vivo	NN	O
.	.	.	O

With	with	IN	O
this	this	DT	O
purpose	purpose	NN	O
,	,	,	O
we	-PRON-	PRP	O
introduced	introduce	VBD	O
pyrimido[5,4-b][1,4]oxazine	pyrimido[5,4-b][1,4]oxazine	NNP	O
as	as	IN	O
the	the	DT	O
core	core	NN	O
using	use	VBG	O
the	the	DT	O
strategy	strategy	NN	O
of	of	IN	O
scaffold	scaffold	JJ	O
hopping	hopping	NN	O
.	.	.	O

We	-PRON-	PRP	O
also	also	RB	O
identified	identify	VBD	O
whether	whether	IN	O
introduction	introduction	NN	O
of	of	IN	O
several	several	JJ	O
conformation	conformation	NN	O
restricted	restrict	VBD	O
azabicyclic	azabicyclic	JJ	O
amines	amine	NNS	O
were	be	VBD	O
beneficial	beneficial	JJ	O
to	to	IN	O
agonistic	agonistic	JJ	O
potency	potency	NN	O
or	or	CC	O
not	not	RB	O
Figure	figure	NN	O
1	1	CD	O
.	.	.	O

In	in	IN	O
this	this	DT	O
paper	paper	NN	O
,	,	,	O
we	-PRON-	PRP	O
described	describe	VBD	O
our	-PRON-	PRP$	O
optimisation	optimisation	NN	O
to	to	TO	O
synthesise	synthesise	VB	O
and	and	CC	O
evaluate	evaluate	VB	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
novel	novel	JJ	O
pyrimido[5,4-b][1,4]oxazine	pyrimido[5,4-b][1,4]oxazine	JJ	O
derivatives	derivative	NNS	O
as	as	IN	O
GPR119	GPR119	NNP	O
agonists	agonist	NNS	O
,	,	,	O
also	also	RB	O
including	include	VBG	O
an	an	DT	O
inÂ	inÂ	NNP	O
vivo	vivo	NNP	O
efficacy	efficacy	NN	O
study	study	NN	O
.	.	.	O

The	the	DT	O
design	design	NN	O
of	of	IN	O
target	target	NN	O
compounds	compound	NNS	O
.	.	.	O

The	the	DT	O
intermediates	intermediate	NNS	O
amine	amine	NN	O
or	or	CC	O
bicyclic	bicyclic	NN	O
amines	amine	NNS	O
3â6	3â6	NNP	O
could	could	MD	O
be	be	VB	O
purchased	purchase	VBN	O
or	or	CC	O
synthesised	synthesise	VBN	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
reported	report	VBN	O
procedures	procedure	NNS	B
.	.	.	O

Coupling	couple	VBG	O
reaction	reaction	NN	O
of	of	IN	O
4,6-dichloro-5-methoxypyrimidine	4,6-dichloro-5-methoxypyrimidine	CD	O
with	with	IN	O
4-amino-3-fluorobenzonitrile	4-amino-3-fluorobenzonitrile	CD	O
in	in	IN	O
DMF	DMF	NNP	O
under	under	IN	O
basic	basic	JJ	O
condition	condition	NN	O
afforded	afford	VBN	O
compound	compound	NNP	O
7	7	CD	O
,	,	,	O
followed	follow	VBN	O
by	by	IN	O
demethylation	demethylation	NN	O
using	use	VBG	O
BBr3	BBr3	NNP	O
solution	solution	NN	O
in	in	IN	O
dichloromethane	dichloromethane	NNP	O
under	under	IN	O
reflux	reflux	NN	O
condition	condition	NN	O
gave	give	VBD	O
hydroxyl	hydroxyl	NNP	O
compound	compound	NNP	O
8	8	CD	O
.	.	.	O

Cyclisation	cyclisation	NN	O
of	of	IN	O
8	8	CD	O
with	with	IN	O
1-bromo-2-chloroethane	1-bromo-2-chloroethane	CD	O
and	and	CC	O
K2CO3	K2CO3	NNP	O
in	in	IN	O
DMF	DMF	NNP	O
generated	generate	VBN	O
key	key	NN	O
intermediate	intermediate	JJ	O
9	9	CD	O
.	.	.	O

BuchwaldâHartwig	BuchwaldâHartwig	NNP	O
reaction	reaction	NN	O
of	of	IN	O
9	9	CD	O
and	and	CC	O
amines	amine	NNS	O
3â6	3â6	NNP	O
with	with	IN	O
Pd2(dba)3	Pd2(dba)3	NNP	O
,	,	,	O
X	X	NNP	O
-	-	NNS	O
Phos	Phos	NNP	O
and	and	CC	O
Cs2CO3	Cs2CO3	NNP	O
under	under	IN	O
reflux	reflux	NN	O
conditions	condition	NNS	O
and	and	CC	O
N2	N2	NNP	O
atmosphere	atmosphere	NN	O
overnight	overnight	RB	O
resulted	result	VBD	O
in	in	IN	O
target	target	NN	O
compounds	compound	NNS	O
10â13	10â13	CD	O
Scheme	scheme	NN	O
1	1	CD	O
.	.	.	O

Synthesis	synthesis	NN	O
of	of	IN	O
compounds	compound	NNS	O
10â13	10â13	CD	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
a	a	DT	O
4-amino-3-fluorobenzonitrile	4-amino-3-fluorobenzonitrile	CD	O
,	,	,	O
K2CO3	K2CO3	NNP	O
,	,	,	O
DMF	DMF	NNP	O
,	,	,	O
65âÂ	65ââ	RB	O
°	°	,	O
C	C	NNP	O
,	,	,	O
overnight	overnight	RB	O
.	.	.	O

b	b	NN	O
1âM	1âm	CD	O
BBr3	BBr3	NNP	O
in	in	IN	O
DCM	DCM	NNP	O
,	,	,	O
anhydrous	anhydrous	JJ	O
DCM	DCM	NNP	O
,	,	,	O
r.	r.	NNP	O
t.	t.	NNP	O
â	â	NNP	O
reflux	reflux	NN	O
,	,	,	O
2âh	2âh	CD	O
.	.	.	O

c	c	NN	O
1-bromo-2-chloroethane	1-bromo-2-chloroethane	CD	O
,	,	,	O
K2CO3	K2CO3	NNP	O
,	,	,	O
DMF	DMF	NNP	O
,	,	,	O
40âÂ	40ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
overnight	overnight	RB	O
.	.	.	O

d	d	NN	O
amines	amine	VBZ	O
3â6	3â6	NNP	O
,	,	,	O
Pd2(dba)3	Pd2(dba)3	NNP	O
,	,	,	O
X	X	NNP	O
-	-	NNP	O
Phos	Phos	NNP	O
,	,	,	O
Cs2CO3	Cs2CO3	NNP	O
,	,	,	O
1,4-Dioxane	1,4-dioxane	CD	O
,	,	,	O
reflux	reflux	NN	O
,	,	,	O
under	under	IN	O
N2	N2	NNP	O
overnight	overnight	RB	O
.	.	.	O

Removing	Removing	NNP	O
Boc	Boc	NNP	O
group	group	NN	O
of	of	IN	O
derivative	derivative	JJ	O
10	10	CD	O
in	in	IN	O
3âM	3âm	CD	O
HCl	HCl	NNP	O
ethanol	ethanol	NN	O
solution	solution	NN	O
obtained	obtain	VBD	O
amine	amine	NN	O
compound	compound	NNP	O
14	14	CD	O
in	in	IN	O
good	good	JJ	O
yield	yield	NN	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
various	various	JJ	O
chloro	chloro	NNS	O
-	-	HYPH	O
fragments	fragment	NNS	O
in	in	IN	O
base	base	NN	O
conditions	condition	NNS	O
to	to	TO	O
receive	receive	VB	O
desired	desire	VBN	O
final	final	JJ	O
compounds	compound	NNS	O
15â20	15â20	CD	O
Scheme	Scheme	NNP	O
2	2	CD	O
.	.	.	O

Synthesis	synthesis	NN	O
of	of	IN	O
compounds	compound	NNS	O
15â20	15â20	CD	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
a	a	LS	O
3âM	3âm	CD	O
HCl	HCl	NNP	O
in	in	IN	O
EtOH	EtOH	NNP	O
,	,	,	O
r.	r.	NNP	O
t.	t.	NNP	O
,	,	,	O
overnight	overnight	RB	O
.	.	.	O

b	b	NN	O
chloro	chloro	NN	O
-	-	HYPH	O
fragments	fragment	NNS	O
,	,	,	O
Et3N	Et3N	NNP	O
,	,	,	O
DCM	DCM	NNP	O
,	,	,	O
r.	r.	NNP	O
t.	t.	NNP	O
,	,	,	O
overnight	overnight	RB	O
or	or	CC	O
Cs2CO3	Cs2CO3	NNP	O
,	,	,	O
DMF	DMF	NNP	O
,	,	,	O
r.	r.	NNP	O
t.	t.	NNP	O
,	,	,	O
overnight	overnight	RB	O
.	.	.	O

The	the	DT	O
general	general	JJ	O
synthetic	synthetic	JJ	O
procedures	procedure	NNS	O
of	of	IN	O
the	the	DT	O
pyrimidooxazine	pyrimidooxazine	NN	O
derivatives	derivative	NNS	O
22â25	22â25	CD	O
were	be	VBD	O
synthesised	synthesise	VBN	O
as	as	IN	O
shown	show	VBN	O
in	in	IN	O
Scheme	Scheme	NNP	O
3	3	CD	O
,	,	,	O
following	follow	VBG	O
similar	similar	JJ	O
methods	method	NNS	O
with	with	IN	O
compounds	compound	NNS	O
15â20	15â20	CD	O
.	.	.	O

Synthesis	synthesis	NN	O
of	of	IN	O
compounds	compound	NNS	O
22â25	22â25	CD	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
a	a	LS	O
3âM	3âm	CD	O
HCl	HCl	NNP	O
in	in	IN	O
EtOH	EtOH	NNP	O
,	,	,	O
r.	r.	NNP	O
t.	t.	NNP	O
,	,	,	O
overnight	overnight	RB	O
.	.	.	O

b	b	NN	O
chloro	chloro	NN	O
-	-	HYPH	O
fragments	fragment	NNS	O
,	,	,	O
Et3N	Et3N	NNP	O
,	,	,	O
DCM	DCM	NNP	O
,	,	,	O
r.	r.	NNP	O
t.	t.	NNP	O
,	,	,	O
overnight	overnight	RB	O
or	or	CC	O
Cs2CO3	Cs2CO3	NNP	O
,	,	,	O
DMF	DMF	NNP	O
,	,	,	O
r.	r.	NNP	O
t.	t.	NNP	O
,	,	,	O
overnight	overnight	RB	O
.	.	.	O

GPR119	gpr119	JJ	O
agonistic	agonistic	JJ	O
activity	activity	NN	O
of	of	IN	O
target	target	NN	O
compounds	compound	NNS	O
10â13	10â13	CD	O
,	,	,	O
15â20	15â20	CD	O
,	,	,	O
and	and	CC	O
22â25	22â25	CD	O
were	be	VBD	O
measured	measure	VBN	O
using	use	VBG	O
a	a	DT	O
reporter	reporter	NN	O
assay	assay	NN	O
with	with	IN	O
the	the	DT	O
human	human	JJ	O
GPR119	GPR119	NNP	O
receptor	receptor	NN	O
stably	stably	RB	O
expressed	express	VBN	O
in	in	IN	O
CHO	CHO	NNP	O
K1	K1	NNP	O
cells	cell	NNS	O
.	.	.	O

A	a	DT	O
GPR119	GPR119	NNP	O
agonist	agonist	NN	O
GSK-1292263	GSK-1292263	NNP	O
was	be	VBD	O
chose	choose	VBN	O
for	for	IN	O
the	the	DT	O
reference	reference	NN	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
expressed	express	VBD	O
the	the	DT	O
activity	activity	NN	O
as	as	IN	O
EC50	EC50	NNP	O
values	value	NNS	O
and	and	CC	O
the	the	DT	O
inherent	inherent	JJ	O
activity	activity	NN	O
IA	IA	NNP	O
as	as	IN	O
percentages	percentage	NNS	O
%	%	NNP	O
max	max	NNP	O
of	of	IN	O
response	response	NN	O
which	which	WDT	O
were	be	VBD	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
reference	reference	NN	O
GSK-1292263	GSK-1292263	NNP	O
defined	define	VBN	O
the	the	DT	O
maximal	maximal	JJ	O
effect	effect	NN	O
activation	activation	NN	O
.	.	.	O

At	at	IN	O
first	first	RB	O
,	,	,	O
we	-PRON-	PRP	O
evaluated	evaluate	VBD	O
pyrimidooxazine	pyrimidooxazine	NN	O
derivatives	derivative	NNS	O
10â13	10â13	CD	O
for	for	IN	O
the	the	DT	O
GPR119	gpr119	JJ	O
agonistic	agonistic	JJ	O
activity	activity	NN	O
and	and	CC	O
intrinsic	intrinsic	JJ	O
activity	activity	NN	O
Table	table	NN	O
1	1	CD	O
.	.	.	O

As	as	IN	O
a	a	DT	O
result	result	NN	O
,	,	,	O
good	good	JJ	O
activities	activity	NNS	O
were	be	VBD	O
observed	observe	VBN	O
with	with	IN	O
compounds	compound	NNS	O
10	10	CD	O
and	and	CC	O
12	12	CD	O
EC50	EC50	NNP	O
=	=	SYM	O
13	13	CD	O
and	and	CC	O
200ânM	200ânm	CD	O
respectively	respectively	RB	O
,	,	,	O
which	which	WDT	O
contained	contain	VBD	O
tropine	tropine	NNP	O
amine	amine	NNP	O
and	and	CC	O
piperidine	piperidine	NNP	O
amine	amine	NNP	O
scaffolds	scaffold	VBZ	O
with	with	IN	O
moderate	moderate	JJ	O
lipophilicity	lipophilicity	NN	O
ClogPâ=â4.0	ClogPâ=â4.0	NNP	O
and	and	CC	O
3.5	3.5	CD	O
respectively	respectively	RB	O
.	.	.	O

%	%	NNP	O
max	max	NNP	O
:	:	:	O
cAMP	cAMP	NNP	O
stimulation	stimulation	NN	O
%	%	NN	O
compared	compare	VBN	O
to	to	IN	O
maximal	maximal	JJ	O
effect	effect	NN	O
of	of	IN	O
GSK1292263	GSK1292263	NNP	O
.	.	.	O

ClogP	ClogP	NNP	O
was	be	VBD	O
calculated	calculate	VBN	O
using	use	VBG	O
ACD	ACD	NNP	O
software	software	NN	O
from	from	IN	O
Discovery	Discovery	NNP	O
Studio	Studio	NNP	O
4.5	4.5	CD	O
.	.	.	O

Next	next	RB	O
,	,	,	O
we	-PRON-	PRP	O
focussed	focusse	VBD	O
on	on	IN	O
the	the	DT	O
modification	modification	NN	O
of	of	IN	O
Boc	Boc	NNP	O
group	group	NN	O
in	in	IN	O
head	head	NN	O
part	part	NN	O
with	with	IN	O
various	various	JJ	O
moieties	moiety	NNS	O
.	.	.	O

The	the	DT	O
biological	biological	JJ	O
results	result	NNS	O
were	be	VBD	O
shown	show	VBN	O
in	in	IN	O
Table	Table	NNP	O
2	2	CD	O
,	,	,	O
all	all	DT	O
compounds	compound	NNS	O
exhibited	exhibit	VBN	O
moderate	moderate	JJ	O
to	to	IN	O
potent	potent	JJ	O
agonistic	agonistic	JJ	O
activities	activity	NNS	O
EC50	ec50	NN	O
values	value	NNS	O
range	range	VBP	O
from	from	IN	O
250ânM	250ânm	CD	O
to	to	IN	O
12ânM	12ânm	CD	O
.	.	.	O

The	the	DT	O
substitution	substitution	NN	O
of	of	IN	O
2-pyrimidyl	2-pyrimidyl	CD	O
on	on	IN	O
the	the	DT	O
nitrogen	nitrogen	NN	O
of	of	IN	O
tropine	tropine	NN	O
ring	ring	NN	O
yielded	yield	VBD	O
compounds	compound	NNS	O
16	16	CD	O
and	and	CC	O
17	17	CD	O
,	,	,	O
which	which	WDT	O
showed	show	VBD	O
the	the	DT	O
moderate	moderate	JJ	O
EC50	EC50	NNP	O
values	value	NNS	O
130ânM	130ânm	CD	O
and	and	CC	O
250ânM	250ânm	CD	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

However	however	RB	O
,	,	,	O
the	the	DT	O
compounds	compound	NNS	O
23	23	CD	O
and	and	CC	O
24	24	CD	O
,	,	,	O
bearing	bear	VBG	O
same	same	JJ	O
substituents	substituent	NNS	O
on	on	IN	O
the	the	DT	O
nitrogen	nitrogen	NN	O
of	of	IN	O
piperidine	piperidine	NNP	O
ring	ring	NN	O
,	,	,	O
demonstrated	demonstrate	VBD	O
significant	significant	JJ	O
agonistic	agonistic	JJ	O
activities	activity	NNS	O
EC50	EC50	NNP	O
=	=	SYM	O
44ânM	44ânm	CD	O
and	and	CC	O
40ânM	40ânm	LS	O
and	and	CC	O
lower	low	JJR	O
lipophilicity	lipophilicity	NN	O
.	.	.	O

But	but	CC	O
the	the	DT	O
reverse	reverse	JJ	O
results	result	NNS	O
were	be	VBD	O
observed	observe	VBN	O
for	for	IN	O
carbamate	carbamate	JJ	O
substituted	substitute	VBN	O
derivatives	derivative	NNS	O
15	15	CD	O
vs.	vs.	IN	O
22	22	CD	O
,	,	,	O
and	and	CC	O
compound	compound	NNP	O
15	15	CD	O
exhibited	exhibit	VBN	O
10	10	CD	O
times	time	NNS	O
EC50	EC50	NNP	O
values	value	NNS	O
than	than	IN	O
compound	compound	NN	O
22	22	CD	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
compound	compound	NNP	O
15	15	CD	O
revealed	reveal	VBD	O
the	the	DT	O
strongest	strong	JJS	O
inherent	inherent	JJ	O
activity	activity	NN	O
%	%	NN	O
max	max	NNP	O
146.5	146.5	CD	O
%	%	NN	O
and	and	CC	O
best	good	JJS	O
agonistic	agonistic	JJ	O
activity	activity	NN	O
EC50	EC50	NNP	O
=	=	SYM	O
12ânM	12ânm	LS	O
with	with	IN	O
suitable	suitable	JJ	O
ClogP	ClogP	NNP	O
value	value	NN	O
3.8	3.8	CD	O
.	.	.	O

Consequently	consequently	RB	O
,	,	,	O
compounds	compound	VBZ	O
15	15	CD	O
and	and	CC	O
10	10	CD	O
were	be	VBD	O
selected	select	VBN	O
and	and	CC	O
examined	examine	VBD	O
the	the	DT	O
oral	oral	JJ	O
glucose	glucose	NN	O
tolerance	tolerance	NN	O
test	test	NN	O
oGTT	ogtt	NN	O
inÂ	inÂ	NNP	O
vivo	vivo	NN	O
as	as	IN	O
promising	promising	JJ	O
GPR119	GPR119	NNP	O
agonists	agonist	NNS	O
.	.	.	O

%	%	NN	O
max	max	NNP	O
:	:	:	O
cAMP	cAMP	NNP	O
stimulation	stimulation	NN	O
%	%	NN	O
compared	compare	VBN	O
to	to	IN	O
maximal	maximal	JJ	O
effect	effect	NN	O
of	of	IN	O
GSK1292263	GSK1292263	NNP	O
.	.	.	O

ClogP	ClogP	NNP	O
was	be	VBD	O
calculated	calculate	VBN	O
using	use	VBG	O
ACD	ACD	NNP	O
software	software	NN	O
from	from	IN	O
Discovery	Discovery	NNP	O
Studio	Studio	NNP	O
4.5	4.5	CD	O
.	.	.	O

Based	base	VBN	O
on	on	IN	O
the	the	DT	O
good	good	JJ	O
agonistic	agonistic	JJ	O
activity	activity	NN	O
,	,	,	O
we	-PRON-	PRP	O
conducted	conduct	VBD	O
oGTT	ogtt	PRP	O
of	of	IN	O
compounds	compound	NNS	O
10	10	CD	O
and	and	CC	O
15	15	CD	O
with	with	IN	O
a	a	DT	O
single	single	JJ	O
dose	dose	NN	O
15	15	CD	O
and	and	CC	O
30âmg	30âmg	CD	O
/	/	SYM	O
kg	kg	NNP	O
in	in	IN	O
C57BL/6N	c57bl/6n	NN	O
mice	mouse	NNS	O
with	with	IN	O
DPP-4	DPP-4	NNP	O
inhibitor	inhibitor	NN	O
vildagliptin	vildagliptin	NNP	O
as	as	IN	O
a	a	DT	O
positive	positive	JJ	O
control	control	NN	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
were	be	VBD	O
outlined	outline	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
2	2	CD	O
,	,	,	O
compounds	compound	VBZ	O
10	10	CD	O
and	and	CC	O
15	15	CD	O
both	both	DT	O
showed	show	VBD	O
blood	blood	NN	O
glucose	glucose	NN	O
reduction	reduction	NN	O
effect	effect	NN	O
in	in	IN	O
dose	dose	RB	O
-	-	HYPH	O
dependent	dependent	JJ	O
manner	manner	NN	O
.	.	.	O

Vildagliptin	Vildagliptin	NNP	O
reduced	reduce	VBD	O
the	the	DT	O
area	area	NN	O
under	under	IN	O
curve	curve	NN	O
from	from	IN	O
0	0	CD	O
to	to	IN	O
120âmin	120âmin	CD	O
AUC0â120âmin	AUC0â120âmin	NNP	O
by	by	IN	O
17.9	17.9	CD	O
%	%	NN	O
Vehicle	vehicle	NN	O
:	:	:	O
24.69âÂ±â3.08	24.69ââ±â3.08	CD	O
,	,	,	O
Vildagliptin	Vildagliptin	NNP	O
:	:	:	O
20.26âÂ±â2.14	20.26ââ±â2.14	CD	O
at	at	IN	O
the	the	DT	O
dose	dose	NN	O
of	of	IN	O
30âmg	30âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
.	.	.	O

Meanwhile	meanwhile	RB	O
compounds	compound	VBZ	O
10	10	CD	O
and	and	CC	O
15	15	CD	O
reduced	reduce	VBN	O
AUC0â120âmin	auc0â120âmin	NN	O
by	by	IN	O
10.7	10.7	CD	O
%	%	NN	O
22.07âÂ±â4.28	22.07ââ±â4.28	CD	O
and	and	CC	O
14.5	14.5	CD	O
%	%	NN	O
21.10âÂ±â3.92	21.10ââ±â3.92	CD	O
at	at	IN	O
the	the	DT	O
dosage	dosage	NN	O
of	of	IN	O
15âmg	15âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

However	however	RB	O
,	,	,	O
10	10	CD	O
and	and	CC	O
15	15	CD	O
showed	show	VBD	O
significant	significant	JJ	O
improved	improve	VBN	O
efficacy	efficacy	NN	O
by	by	IN	O
the	the	DT	O
reduction	reduction	NN	O
of	of	IN	O
value	value	NN	O
to	to	IN	O
18.8	18.8	CD	O
%	%	NN	O
20.05âÂ±â2.27	20.05ââ±â2.27	CD	O
and	and	CC	O
23.4	23.4	CD	O
%	%	NN	O
18.91âÂ±â2.58	18.91ââ±â2.58	CD	O
at	at	IN	O
the	the	DT	O
dosage	dosage	NN	O
of	of	IN	O
30âmg	30âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Single	single	JJ	O
dose	dose	NN	O
of	of	IN	O
compounds	compound	NNS	O
10	10	CD	O
and	and	CC	O
15	15	CD	O
on	on	IN	O
oGTT	ogtt	CD	O
in	in	IN	O
C57BL/6N	c57bl/6n	NN	O
mice	mouse	NNS	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
are	be	VBP	O
presented	present	VBN	O
as	as	IN	O
the	the	DT	O
meanâÂ±âSE	meanâÂ±âSE	NNP	O
.	.	NNP	O

*	*	NFP	O
pâ<â0.05	pâ<â0.05	NNP	O
compared	compare	VBN	O
to	to	IN	O
vehicle	vehicle	NN	O
group	group	NN	O
nâ=â8	nâ=â8	NNP	O
.	.	.	O

In	in	IN	O
summary	summary	NN	O
,	,	,	O
we	-PRON-	PRP	O
have	have	VBP	O
designed	design	VBN	O
,	,	,	O
synthesised	synthesise	VBN	O
and	and	CC	O
biologically	biologically	RB	O
evaluated	evaluate	VBD	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
novel	novel	JJ	O
pyrimido[5,4-b][1,4]oxazine	pyrimido[5,4-b][1,4]oxazine	JJ	O
derivatives	derivative	NNS	O
as	as	IN	O
potent	potent	JJ	O
GPR119	GPR119	NNP	O
agonists	agonist	NNS	O
.	.	.	O

In	in	IN	O
vitro	vitro	FW	O
,	,	,	O
half	half	NN	O
derivatives	derivative	NNS	O
exhibited	exhibit	VBN	O
strong	strong	JJ	O
EC50	EC50	NNP	O
values	value	NNS	O
<	<	XX	O
100ânM	100ânm	CD	O
.	.	.	O

Among	among	IN	O
the	the	DT	O
aliphatic	aliphatic	JJ	O
amine	amine	NN	O
moieties	moiety	NNS	O
of	of	IN	O
this	this	DT	O
scaffold	scaffold	NN	O
,	,	,	O
the	the	DT	O
compound	compound	NN	O
10	10	CD	O
with	with	IN	O
tropine	tropine	NNP	O
amine	amine	NNP	O
ring	ring	NN	O
displayed	display	VBD	O
much	much	RB	O
more	more	RBR	O
potent	potent	JJ	O
agonistic	agonistic	JJ	O
activity	activity	NN	O
than	than	IN	O
piperidine	piperidine	NNP	O
amine	amine	NNP	O
and	and	CC	O
other	other	JJ	O
rigid	rigid	JJ	O
bicyclic	bicyclic	NN	O
amines	amine	NNS	O
.	.	.	O

In	in	IN	O
the	the	DT	O
further	further	JJ	O
optimisation	optimisation	NN	O
of	of	IN	O
N	N	NNP	O
-	-	HYPH	O
substitution	substitution	NN	O
,	,	,	O
only	only	RB	O
isopropyl	isopropyl	NNP	O
carbamate	carbamate	NN	O
of	of	IN	O
tropine	tropine	NN	O
ring	ring	NN	O
15	15	CD	O
improved	improve	VBD	O
the	the	DT	O
EC50	EC50	NNP	O
values	value	NNS	O
and	and	CC	O
showed	show	VBD	O
the	the	DT	O
greatest	great	JJS	O
inherent	inherent	JJ	O
activity	activity	NN	O
.	.	.	O

Accordingly	accordingly	RB	O
,	,	,	O
compounds	compound	VBZ	O
10	10	CD	O
and	and	CC	O
15	15	CD	O
were	be	VBD	O
conducted	conduct	VBN	O
the	the	DT	O
oGTT	ogtt	NN	O
in	in	IN	O
C57BL/6N	c57bl/6n	NN	O
mice	mouse	NNS	O
.	.	.	O

Both	both	DT	O
two	two	CD	O
agonists	agonist	NNS	O
demonstrated	demonstrate	VBD	O
blood	blood	NN	O
glucose	glucose	NN	O
reduction	reduction	NN	O
effect	effect	NN	O
in	in	IN	O
a	a	DT	O
dose	dose	RB	O
-	-	HYPH	O
dependent	dependent	JJ	O
manner	manner	NN	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
the	the	DT	O
optimised	optimised	JJ	O
compound	compound	NNP	O
15	15	CD	O
was	be	VBD	O
exerted	exert	VBN	O
improved	improve	VBN	O
23.4	23.4	CD	O
%	%	NN	O
reduction	reduction	NN	O
in	in	IN	O
blood	blood	NN	O
glucose	glucose	VBP	O
AUC0â2h	AUC0â2h	NNP	O
at	at	IN	O
the	the	DT	O
dose	dose	NN	O
of	of	IN	O
30âmg	30âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
comparing	compare	VBG	O
with	with	IN	O
Vildagliptin	Vildagliptin	NNP	O
17.9	17.9	CD	O
%	%	NN	O
reduction	reduction	NN	O
.	.	.	O

Follow	follow	VB	O
-	-	HYPH	O
up	up	RP	O
studies	study	NNS	O
and	and	CC	O
their	-PRON-	PRP$	O
results	result	NNS	O
will	will	MD	O
be	be	VB	O
reported	report	VBN	O
in	in	IN	O
due	due	JJ	O
course	course	NN	O
.	.	.	O

All	all	DT	O
starting	start	VBG	O
materials	material	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
commercial	commercial	JJ	O
suppliers	supplier	NNS	O
and	and	CC	O
used	use	VBN	O
without	without	IN	O
further	further	JJ	O
purification	purification	NN	O
.	.	.	O

1H	1H	NNP	O
-	-	:	O
NMR	NMR	NNP	O
and	and	CC	O
13C	13C	NNP	O
-	-	HYPH	O
NMR	NMR	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
on	on	IN	O
a	a	DT	O
Bruker	Bruker	NNP	O
AVANCE	avance	NN	O
III	iii	CD	O
HD	hd	NN	O
600	600	CD	O
600âHz	600âhz	CD	O
spectrometer	spectrometer	VB	O
.	.	.	O

Chemical	chemical	NN	O
shifts	shift	NNS	O
are	be	VBP	O
reported	report	VBN	O
in	in	IN	O
parts	part	NNS	O
per	per	IN	O
million	million	CD	O
ppm	ppm	NNP	O
downfield	downfield	NN	O
relative	relative	JJ	O
to	to	IN	O
tetramethylsilane	tetramethylsilane	NN	O
as	as	IN	O
an	an	DT	O
internal	internal	JJ	O
standard	standard	NN	O
.	.	.	O

Peak	peak	VB	O
splitting	splitting	NN	O
patterns	pattern	NNS	O
are	be	VBP	O
abbreviated	abbreviate	VBN	O
as	as	IN	O
s	s	NNP	O
singlet	singlet	NNP	O
,	,	,	O
br	br	NNP	O
s	s	NNP	O
broad	broad	JJ	O
singlet	singlet	NNP	O
,	,	,	O
d	d	NNP	O
doublet	doublet	NNP	O
,	,	,	O
t	t	NNP	O
triplet	triplet	NN	O
,	,	,	O
dd	dd	NNP	O
doublet	doublet	NNP	O
of	of	IN	O
doublet	doublet	NNP	O
,	,	,	O
and	and	CC	O
m	m	NNP	O
multiplet	multiplet	NN	O
.	.	.	O

MS	MS	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
on	on	IN	O
a	a	DT	O
Thermo	Thermo	NNP	O
Fisher	Fisher	NNP	O
LCQ	LCQ	NNP	O
Fleet	Fleet	NNP	O
.	.	.	O

HR	HR	NNP	O
-	-	HYPH	O
MS	MS	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
on	on	IN	O
an	an	DT	O
AB	AB	NNP	O
SCIEX	SCIEX	NNP	O
Triple	Triple	NNP	O
TOF	TOF	NNP	O
5600	5600	CD	O
+	+	SYM	O
.	.	.	O

TLC	TLC	NNP	O
was	be	VBD	O
performed	perform	VBN	O
on	on	IN	O
silica	silica	NN	O
F254	F254	NNP	O
purchased	purchase	VBN	O
from	from	IN	O
Branch	Branch	NNP	O
of	of	IN	O
Qingdao	Qingdao	NNP	O
Haiyang	Haiyang	NNP	O
Chemical	Chemical	NNP	O
Co.	Co.	NNP	O
Qingdao	Qingdao	NNP	O
,	,	,	O
China	China	NNP	O
and	and	CC	O
detected	detect	VBN	O
by	by	IN	O
UV	UV	NNP	O
light	light	NN	O
at	at	IN	O
254	254	CD	O
,	,	,	O
365ânm	365ânm	CD	O
or	or	CC	O
by	by	IN	O
charring	char	VBG	O
with	with	IN	O
sulphuric	sulphuric	JJ	O
acid	acid	NN	O
.	.	.	O

Column	column	NN	O
chromatography	chromatography	NN	O
was	be	VBD	O
performed	perform	VBN	O
on	on	IN	O
silica	silica	NNP	O
gel	gel	NNP	O
column	column	NNP	O
200â300	200â300	CD	O
mesh	mesh	NN	O
,	,	,	O
Branch	Branch	NNP	O
of	of	IN	O
Qingdao	Qingdao	NNP	O
Haiyang	Haiyang	NNP	O
Chemical	Chemical	NNP	O
Co.	Co.	NNP	O
.	.	.	O

Analytical	analytical	JJ	O
HPLC	hplc	NN	O
was	be	VBD	O
performed	perform	VBN	O
on	on	IN	O
a	a	DT	O
Waters	Waters	NNP	O
AcquityÂ	AcquityÂ	NNP	O
®	®	NN	O
Arcâ¢	arcâ¢	NN	O
with	with	IN	O
2998	2998	CD	O
PDA	PDA	NNP	O
detector	detector	NN	O
and	and	CC	O
all	all	DT	O
final	final	JJ	O
compounds	compound	NNS	O
possessed	possess	VBD	O
purities	purity	NNS	O
of	of	IN	O
>	>	XX	O
90	90	CD	O
%	%	NN	O
after	after	IN	O
purification	purification	NN	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
4,6-dichloro-5-methoxypyrimidine	4,6-dichloro-5-methoxypyrimidine	CD	O
1âg	1âg	CD	O
,	,	,	O
5.7âmmol	5.7âmmol	NNP	O
in	in	IN	O
DMF	DMF	NNP	O
20âml	20âml	CD	O
,	,	,	O
4-amino-3-fluorobenzonitrile	4-amino-3-fluorobenzonitrile	CD	O
0.6âg	0.6âg	CD	O
,	,	,	O
4.4âmmol	4.4âmmol	CD	O
and	and	CC	O
K2CO3	K2CO3	NNP	O
2.4âg	2.4âg	CD	O
,	,	,	O
17âmmol	17âmmol	NNP	O
were	be	VBD	O
added	add	VBN	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
stirrd	stirrd	NN	O
at	at	IN	O
65âÂ	65âÂ	NNP	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
overnight	overnight	RB	O
.	.	.	O

Then	then	RB	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
poured	pour	VBN	O
into	into	IN	O
ice	ice	NN	O
water	water	NN	O
.	.	.	O

The	the	DT	O
mix	mix	NN	O
solution	solution	NN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
ethyl	ethyl	NNP	O
acetate	acetate	NNP	O
for	for	IN	O
two	two	CD	O
times	time	NNS	O
,	,	,	O
washed	wash	VBD	O
with	with	IN	O
brine	brine	NN	O
for	for	IN	O
two	two	CD	O
times	time	NNS	O
.	.	.	O

The	the	DT	O
organic	organic	JJ	O
layer	layer	NN	O
was	be	VBD	O
dried	dry	VBN	O
over	over	IN	O
MgSO4	MgSO4	NNP	O
,	,	,	O
filtered	filter	VBN	O
and	and	CC	O
evaporated	evaporate	VBD	O
.	.	.	O

The	the	DT	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
column	column	NN	O
chromatography	chromatography	NN	O
petroleum	petroleum	NN	O
ether	ether	NN	O
:	:	:	O
EtOAc	EtOAc	NNS	O
=	=	SYM	O
3	3	CD	O
:	:	SYM	O
1	1	CD	O
to	to	TO	O
afford	afford	VB	O
the	the	DT	O
desired	desire	VBN	O
product	product	NN	O
as	as	IN	O
a	a	DT	O
claybank	claybank	NN	O
solid	solid	JJ	O
0.68âg	0.68âg	CD	O
,	,	,	O
55	55	CD	O
%	%	NN	O
.	.	.	O

1H	1h	LS	O
-	-	:	O
NMR	NMR	NNP	O
600âMHz	600âmhz	CD	O
,	,	,	O
CDCl3	CDCl3	NNP	O
Î	Î	NNP	O
´	´	CD	O
ppm	ppm	NN	O
:	:	:	O
8.94	8.94	CD	O
t	t	NNP	O
,	,	,	O
Jâ=â8.8âHz	Jâ=â8.8âHz	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
8.35	8.35	CD	O
s	s	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
7.73	7.73	CD	O
s	s	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
7.59	7.59	CD	O
d	d	NNP	O
,	,	,	O
Jâ=â8.8âHz	Jâ=â8.8âHz	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
7.52	7.52	CD	O
d	d	NNP	O
,	,	,	O
Jâ=â10.2âHz	Jâ=â10.2âHz	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
3.10	3.10	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
.	.	.	O

MS	MS	NNP	O
-	-	HYPH	O
ESI	ESI	NNP	O
:	:	:	O
Mâ+âH]+	mâ+âh]+	IN	O
:	:	:	O
279.3	279.3	CD	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
compound	compound	NN	O
7	7	CD	O
0.5âg	0.5âg	CD	O
,	,	,	O
1.9âmmol	1.9âmmol	CD	O
in	in	IN	O
anhydrous	anhydrous	JJ	O
dichloromethane	dichloromethane	NN	O
15âml	15âml	CD	O
,	,	,	O
1âM	1âm	CD	O
BBr3	BBr3	NNP	O
in	in	IN	O
dichloromethane	dichloromethane	NN	O
solution	solution	NN	O
5.7âml	5.7âml	NNP	O
,	,	,	O
5.7âmmol	5.7âmmol	NNP	O
was	be	VBD	O
added	add	VBN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
r.	r.	NNP	O
t.	t.	NNP	O
The	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
reflux	reflux	VBN	O
for	for	IN	O
2âh	2âh	CD	O
.	.	.	O

Then	then	RB	O
the	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
quenched	quench	VBN	O
by	by	IN	O
water	water	NN	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
dichloromethane	dichloromethane	NNP	O
for	for	IN	O
two	two	CD	O
times	time	NNS	O
,	,	,	O
washed	wash	VBN	O
by	by	IN	O
brine	brine	NN	O
for	for	IN	O
two	two	CD	O
times	time	NNS	O
.	.	.	O

The	the	DT	O
organic	organic	JJ	O
layer	layer	NN	O
was	be	VBD	O
dried	dry	VBN	O
over	over	IN	O
MgSO4	MgSO4	NNP	O
,	,	,	O
filtered	filter	VBN	O
and	and	CC	O
evaporated	evaporate	VBD	O
.	.	.	O

The	the	DT	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
column	column	NN	O
chromatography	chromatography	NN	O
petroleum	petroleum	NN	O
ether	ether	NN	O
:	:	:	O
EtOAc	EtOAc	NNS	O
=	=	SYM	O
1	1	CD	O
:	:	SYM	O
1	1	CD	O
to	to	TO	O
give	give	VB	O
the	the	DT	O
desired	desire	VBN	O
product	product	NN	O
as	as	IN	O
a	a	DT	O
yellow	yellow	JJ	O
solid	solid	NN	O
0.3âg	0.3âg	CD	O
,	,	,	O
72	72	CD	O
%	%	NN	O
.	.	.	O

1H	1h	LS	O
-	-	:	O
NMR	NMR	NNP	O
600âMHz	600âmhz	CD	O
,	,	,	O
CDCl3	CDCl3	NNP	O
Î	Î	NNP	O
´	´	CD	O
ppm	ppm	NN	O
:	:	:	O
8.92	8.92	CD	O
t	t	NN	O
,	,	,	O
Jâ=â8.4âHz	jâ=â8.4âhz	NN	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
8.32	8.32	CD	O
s	s	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
7.68	7.68	CD	O
s	s	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
7.53	7.53	CD	O
d	d	NNP	O
,	,	,	O
Jâ=â8.6âHz	Jâ=â8.6âHz	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
7.46	7.46	CD	O
d	d	NN	O
,	,	,	O
Jâ=â10.8âHz	jâ=â10.8âhz	NN	O
,	,	,	O
1H	1H	NNP	O
.	.	.	O

MS	MS	NNP	O
-	-	HYPH	O
ESI	ESI	NNP	O
:	:	:	O
Mâ+âH]+	mâ+âh]+	IN	O
:	:	:	O
265.1	265.1	CD	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
compound	compound	NN	O
8	8	CD	O
0.4âg	0.4âg	CD	O
,	,	,	O
1.4âmmol	1.4âmmol	CD	O
in	in	IN	O
DMF	DMF	NNP	O
10âml	10âml	CD	O
,	,	,	O
1-bromo-2-chloroethane	1-bromo-2-chloroethane	NNP	O
0.62âg	0.62âg	CD	O
,	,	,	O
4.3âmmol	4.3âmmol	CD	O
and	and	CC	O
K2CO3	K2CO3	NNP	O
0.6âg	0.6âg	CD	O
,	,	,	O
4.3âmmol	4.3âmmol	CD	O
were	be	VBD	O
added	add	VBN	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
40âÂ	40ââ	CD	O
°	°	NNS	O
C	C	NNP	O
for	for	IN	O
overnight	overnight	RB	O
.	.	.	O

Then	then	RB	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
poured	pour	VBN	O
into	into	IN	O
ice	ice	NN	O
water	water	NN	O
.	.	.	O

The	the	DT	O
mix	mix	NN	O
solution	solution	NN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
ethyl	ethyl	NNP	O
acetate	acetate	NNP	O
for	for	IN	O
two	two	CD	O
times	time	NNS	O
,	,	,	O
washed	wash	VBD	O
with	with	IN	O
brine	brine	NN	O
for	for	IN	O
two	two	CD	O
times	time	NNS	O
.	.	.	O

The	the	DT	O
organic	organic	JJ	O
layer	layer	NN	O
was	be	VBD	O
dried	dry	VBN	O
over	over	IN	O
MgSO4	MgSO4	NNP	O
,	,	,	O
filtered	filter	VBN	O
and	and	CC	O
evaporated	evaporate	VBD	O
.	.	.	O

The	the	DT	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
column	column	NN	O
chromatography	chromatography	NN	O
petroleum	petroleum	NN	O
ether	ether	NN	O
:	:	:	O
EtOAc	EtOAc	NNS	O
=	=	SYM	O
2	2	CD	O
:	:	SYM	O
1	1	LS	O
to	to	TO	O
afford	afford	VB	O
the	the	DT	O
desired	desire	VBN	O
product	product	NN	O
as	as	IN	O
a	a	DT	O
claybank	claybank	NN	O
solid	solid	JJ	O
0.68âg	0.68âg	CD	O
,	,	,	O
55	55	CD	O
%	%	NN	O
.	.	.	O

1H	1h	LS	O
-	-	:	O
NMR	NMR	NNP	O
600âMHz	600âmhz	CD	O
,	,	,	O
CDCl3	CDCl3	NNP	O
Î	Î	NNP	O
´	´	CD	O
ppm	ppm	NN	O
:	:	:	O
8.04	8.04	CD	O
s	s	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
8.35	8.35	CD	O
s	s	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
7.73â7.44	7.73â7.44	NNP	O
m	m	NNP	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
4.51	4.51	CD	O
t	t	NN	O
,	,	,	O
Jâ=â4.4âHz	jâ=â4.4âhz	NN	O
,	,	,	O
2H	2H	NNP	O
,	,	,	O
3.95	3.95	CD	O
t	t	NN	O
,	,	,	O
Jâ=â4.3âHz	Jâ=â4.3âHz	NNP	O
,	,	,	O
2H	2H	NNP	O
.	.	.	O

MS	MS	NNP	O
-	-	HYPH	O
ESI	ESI	NNP	O
:	:	:	O
Mâ+âH]+	mâ+âh]+	IN	O
:	:	:	O
291.5	291.5	CD	O
.	.	.	O

To	to	IN	O
the	the	DT	O
solution	solution	NN	O
of	of	IN	O
compound	compound	NN	O
9	9	CD	O
0.22âmmol	0.22âmmol	NNP	O
and	and	CC	O
substituted	substitute	VBN	O
amines	amine	NNS	O
0.22âmmol	0.22âmmol	NNP	O
in	in	IN	O
1,4-dioxane	1,4-dioxane	NN	O
2âml	2âml	CD	O
,	,	,	O
Pd2(dba)3	Pd2(dba)3	NNP	O
0.05âmmol	0.05âmmol	NNP	O
,	,	,	O
X	X	NNP	O
-	-	NNS	O
Phos	Phos	NNP	O
0.05âmmol	0.05âmmol	NNP	O
,	,	,	O
and	and	CC	O
Cs2CO3	Cs2CO3	NNP	O
0.55âmmol	0.55âmmol	NNP	O
were	be	VBD	O
added	add	VBN	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
heated	heat	VBN	O
to	to	IN	O
reflux	reflux	VBG	O
under	under	IN	O
nitrogen	nitrogen	NN	O
gas	gas	NN	O
for	for	IN	O
overnight	overnight	RB	O
.	.	.	O

Then	then	RB	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
diluted	dilute	VBN	O
with	with	IN	O
ethyl	ethyl	NN	O
acetate	acetate	NNP	O
,	,	,	O
washed	wash	VBD	O
with	with	IN	O
brine	brine	NN	O
,	,	,	O
dried	dry	VBN	O
over	over	IN	O
MgSO4	MgSO4	NNP	O
,	,	,	O
and	and	CC	O
evaporated	evaporate	VBD	O
.	.	.	O

The	the	DT	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
column	column	NN	O
chromatography	chromatography	NN	O
to	to	TO	O
give	give	VB	O
the	the	DT	O
product	product	NN	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
compound	compound	NN	O
10	10	CD	O
1âmmol	1âmmol	CD	O
in	in	IN	O
3âM	3âm	CD	O
HCl	HCl	NNP	O
/	/	SYM	O
EtOH	EtOH	NNP	O
40âml	40âml	CD	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
r.	r.	NNP	O
t.	t.	NNP	O
for	for	IN	O
overnight	overnight	RB	O
.	.	.	O

Then	then	RB	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
filtered	filter	VBN	O
to	to	TO	O
obtain	obtain	VB	O
the	the	DT	O
product	product	NN	O
14	14	CD	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
used	use	VBN	O
for	for	IN	O
next	next	JJ	O
step	step	NN	O
without	without	IN	O
purification	purification	NN	O
.	.	.	O

MS	MS	NNP	O
-	-	HYPH	O
ESI	ESI	NNP	O
:	:	:	O
Mâ+âH]+	mâ+âh]+	IN	O
:	:	:	O
381.3	381.3	CD	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
compound	compound	NN	O
14	14	CD	O
0.26âmmol	0.26âmmol	NNP	O
in	in	IN	O
DMF	DMF	NNP	O
3âml	3âml	CD	O
,	,	,	O
chloro	chloro	NN	O
-	-	HYPH	O
fragments	fragment	NNS	O
0.34âmmol	0.34âmmol	NNP	O
and	and	CC	O
K2CO3	K2CO3	NNP	O
1âmmol	1âmmol	CD	O
were	be	VBD	O
added	add	VBN	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
r.	r.	NNP	O
t.	t.	NNP	O
for	for	IN	O
overnight	overnight	RB	O
.	.	.	O

Then	then	RB	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
poured	pour	VBN	O
into	into	IN	O
ice	ice	NN	O
water	water	NN	O
.	.	.	O

The	the	DT	O
mix	mix	NN	O
solution	solution	NN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
ethyl	ethyl	NNP	O
acetate	acetate	NNP	O
for	for	IN	O
two	two	CD	O
times	time	NNS	O
,	,	,	O
washed	wash	VBD	O
with	with	IN	O
brine	brine	NN	O
for	for	IN	O
2	2	CD	O
times	time	NNS	O
.	.	.	O

The	the	DT	O
organic	organic	JJ	O
layer	layer	NN	O
was	be	VBD	O
dried	dry	VBN	O
over	over	IN	O
MgSO4	MgSO4	NNP	O
,	,	,	O
filtered	filter	VBN	O
and	and	CC	O
evaporated	evaporate	VBD	O
.	.	.	O

The	the	DT	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
column	column	NN	O
chromatography	chromatography	NN	O
to	to	TO	O
afford	afford	VB	O
the	the	DT	O
desired	desire	VBN	O
product	product	NN	O
.	.	.	O

Follow	follow	VB	O
the	the	DT	O
similar	similar	JJ	O
procedure	procedure	NN	O
of	of	IN	O
14	14	CD	O
.	.	.	O

Yellow	yellow	JJ	O
solid	solid	JJ	O
,	,	,	O
72	72	CD	O
%	%	NN	O
yield	yield	NN	O
.	.	.	O

MS	MS	NNP	O
-	-	HYPH	O
ESI	ESI	NNP	O
:	:	:	O
Mâ+âH]+	mâ+âh]+	IN	O
:	:	:	O
355.7	355.7	CD	O
.	.	.	O

CHO	CHO	NNP	O
K1	K1	NNP	O
cells	cell	NNS	O
stably	stably	RB	O
transfected	transfecte	VBN	O
with	with	IN	O
human	human	JJ	O
GPR119	GPR119	NNP	O
were	be	VBD	O
grown	grow	VBN	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
95%O2	95%o2	CD	O
and	and	CC	O
5	5	CD	O
%	%	NN	O
CO2	CO2	NNP	O
in	in	IN	O
75âcm	75âcm	CD	O
flasks	flask	NNS	O
containing	contain	VBG	O
DMEM	DMEM	NNP	O
/	/	SYM	O
F12	F12	NNP	O
1:1	1:1	NNP	O
media	medium	NNS	O
with	with	IN	O
added	add	VBN	O
10	10	CD	O
%	%	NN	O
FBS	FBS	NNP	O
GibcoÂ	GibcoÂ	NNP	O
®	®	NNPS	O
,	,	,	O
Geneticin	Geneticin	NNP	O
GibcoÂ	GibcoÂ	NNP	O
®	®	NNPS	O
and	and	CC	O
grown	grow	VBN	O
until	until	IN	O
90	90	CD	O
%	%	NN	O
confluent	confluent	NN	O
.	.	.	O

Cells	cell	NNS	O
were	be	VBD	O
then	then	RB	O
washed	wash	VBN	O
PBS	PBS	NNP	O
,	,	,	O
lifted	lift	VBN	O
with	with	IN	O
cell	cell	NN	O
dissociation	dissociation	NN	O
solution	solution	NN	O
InvtrogenÂ	InvtrogenÂ	NNP	O
®	®	NNP	O
,	,	,	O
counted	count	VBN	O
and	and	CC	O
used	use	VBN	O
for	for	IN	O
cAMP	camp	NN	O
accumulation	accumulation	NN	O
assays	assay	NNS	O
and/or	and/or	CC	O
passaging	passaging	NN	O
1:10	1:10	CD	O
.	.	.	O

Following	follow	VBG	O
the	the	DT	O
manufacturerâs	manufacturerâs	CD	O
instructions	instruction	NNS	O
for	for	IN	O
the	the	DT	O
LANCEÂ	LANCEÂ	NNP	O
®	®	NNPS	O
Ultra	Ultra	NNP	O
cAMP	camp	NN	O
assay	assay	NN	O
Perkin	Perkin	NNP	O
Elmer	Elmer	NNP	O
,	,	,	O
cell	cell	NN	O
transfected	transfecte	VBN	O
with	with	IN	O
hGPR119	hGPR119	NNP	O
were	be	VBD	O
centrifuged	centrifuge	VBN	O
1000ârpm	1000ârpm	CD	O
,	,	,	O
5âmin	5âmin	LS	O
,	,	,	O
re	re	NN	O
-	-	VBN	O
suspended	suspend	VBN	O
in	in	IN	O
cAMP	cAMP	NNP	O
assay	assay	NNP	O
buffer	buffer	NNP	O
HBSS	HBSS	NNP	O
,	,	,	O
0.1	0.1	CD	O
%	%	NN	O
BSA	BSA	NNP	O
,	,	,	O
0.5âmM	0.5âmm	CD	O
IBMX	ibmx	NN	O
and	and	CC	O
5âmM	5âmm	CD	O
HEPES	hepe	NNS	O
and	and	CC	O
seeded	seed	VBD	O
at	at	IN	O
5000	5000	CD	O
cells	cell	NNS	O
/	/	SYM	O
well	well	RB	O
in	in	IN	O
optiplate-384	optiplate-384	NNP	O
Perkin	Perkin	NNP	O
Elmer	Elmer	NNP	O
.	.	.	O

Cells	cell	NNS	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
compounds	compound	NNS	O
or	or	CC	O
reference	reference	NN	O
GSK1292263	gsk1292263	NN	O
over	over	IN	O
a	a	DT	O
range	range	NN	O
of	of	IN	O
concentrations	concentration	NNS	O
10âÎ¼M-0.6âÎ¼M	10âî¼m-0.6âî¼m	CD	O
and	and	CC	O
incubated	incubate	VBN	O
for	for	IN	O
1âh	1âh	CD	O
.	.	.	O

Cell	cell	NN	O
lysis	lysis	NN	O
buffers	buffer	NNS	O
4X	4X	NNP	O
Eu	Eu	NNP	O
-	-	HYPH	O
cAMP	camp	NN	O
tracer	tracer	NN	O
solution	solution	NN	O
and	and	CC	O
4X	4X	NNP	O
ULightâ¢-anti	ULightâ¢-anti	NNP	O
-	-	HYPH	O
cAMP	camp	NN	O
solution	solution	NN	O
were	be	VBD	O
added	add	VBN	O
to	to	IN	O
each	each	DT	O
well	well	RB	O
,	,	,	O
and	and	CC	O
the	the	DT	O
plates	plate	NNS	O
were	be	VBD	O
incubated	incubate	VBN	O
at	at	IN	O
r.	r.	NNP	O
t.	t.	NNP	O
for	for	IN	O
1âh	1âh	CD	O
before	before	IN	O
being	be	VBG	O
read	read	VBN	O
on	on	IN	O
Envision	envision	NN	O
Perkin	Perkin	NNP	O
Elmer	Elmer	NNP	O
.	.	.	O

The	the	DT	O
assay	assay	NN	O
was	be	VBD	O
performed	perform	VBN	O
for	for	IN	O
three	three	CD	O
replicates	replicate	NNS	O
for	for	IN	O
each	each	DT	O
concentration	concentration	NN	O
.	.	.	O

For	for	IN	O
the	the	DT	O
acute	acute	JJ	O
single	single	JJ	O
dose	dose	NN	O
study	study	NN	O
,	,	,	O
vehicle	vehicle	NN	O
0.5	0.5	CD	O
%	%	NN	O
carboxymethylcellulose	carboxymethylcellulose	NN	O
sodium	sodium	NN	O
,	,	,	O
10âml	10âml	CD	O
/	/	SYM	O
kg	kg	NN	O
,	,	,	O
compound	compound	NNP	O
10	10	CD	O
,	,	,	O
compound	compound	NNP	O
15	15	CD	O
15	15	CD	O
and	and	CC	O
30âmg	30âmg	CD	O
/	/	SYM	O
kg	kg	NNP	O
and	and	CC	O
vildagliptin	vildagliptin	NNP	O
30âmg	30âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
were	be	VBD	O
administered	administer	VBN	O
to	to	IN	O
C57BL/6N	c57bl/6n	NN	O
mice	mouse	NNS	O
after	after	IN	O
16-h	16-h	CD	O
starvation	starvation	NN	O
,	,	,	O
then	then	RB	O
the	the	DT	O
oral	oral	JJ	O
glucose	glucose	NN	O
tolerance	tolerance	NN	O
test	test	NN	O
3âg	3âg	CD	O
/	/	SYM	O
kg	kg	NNP	O
was	be	VBD	O
conducted	conduct	VBN	O
after	after	IN	O
4âh	4âh	CD	O
of	of	IN	O
the	the	DT	O
single	single	JJ	O
dose	dose	NN	O
,	,	,	O
the	the	DT	O
blood	blood	NN	O
glucose	glucose	VBP	O
level	level	NN	O
at	at	IN	O
0	0	CD	O
,	,	,	O
15	15	CD	O
,	,	,	O
30	30	CD	O
,	,	,	O
60	60	CD	O
,	,	,	O
90	90	CD	O
,	,	,	O
and	and	CC	O
120âmin	120âmin	LS	O
were	be	VBD	O
recorded	record	VBN	O
for	for	IN	O
area	area	NN	O
under	under	IN	O
curve	curve	NN	O
calculation	calculation	NN	O
AUC0â2h	AUC0â2h	NNP	O
.	.	.	O

AUC0â2h(mmol	AUC0â2h(mmol	NNP	O
/	/	SYM	O
L	L	NNP	O
=	=	NFP	O
BG0+BG15)Ã0.25/2	BG0+BG15)Ã0.25/2	NNP	O
+	+	SYM	O
BG15+BG30)Ã0.25/2	BG15+BG30)Ã0.25/2	NNP	O
+	+	CC	O
BG30+BG60)Ã0.5/2	BG30+BG60)Ã0.5/2	NNP	O
+	+	SYM	O
BG60+BG90)Ã0.5/2	BG60+BG90)Ã0.5/2	NNP	O
+	+	SYM	O
BG90+BG120)Ã0.5/2	BG90+BG120)Ã0.5/2	NNP	O
.	.	.	O

